Enhanced Plasma Soluble CD40 Ligand Levels in Essential Hypertensive Patients With Blunted Nocturnal Blood Pressure Decrease

American Journal of Hypertension

Volumn 20, Issue 1, 2007, Pages 70-76

  Desideri, Giovambattista ^a   Cipollone, Francesco ^b   Valeri, Letizia ^a   Grassi, Davide ^a   Necozione, Stefano ^a   Croce, Giuseppe ^a   Passacquale, Gabriella ^a   Garofalo, Angela ^a   Lippi, Cristina ^a   Mezzetti, Andrea ^b   Ferri, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

atherosclerosis; blood pressure measurement monitoring; CD40L; hypertension; isoprostanes

Indexed keywords

CD40 LIGAND;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; HUMAN; HUMAN TISSUE; INTIMA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS;

BLOOD PRESSURE; C-REACTIVE PROTEIN; CAROTID ARTERY, COMMON; CD40 LIGAND; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION; ISOPROSTANES; MIDDLE AGED; PLATELET ACTIVATION;

EID: 33845800350     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.06.007     Document Type: Article

References (28)

1. Cuspidi C., Macca G., Sampieri L., Fusi V., Severgnini B., Michey I., Salerno M., Magrini F., and Zanchetti A. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed hypertensive patients. J Hypertens 19 (2001) 1539-1545
2. Pierdomenico S., Lapenna D., Guglielmi M.D., Costantini F., Romano F., Schiavone C., Cuccurullo F., and Mezzetti A. Arterial disease in dipper and non-dipper hypertensive patients. Am J Hypertens 10 (1997) 511-518
3. Shimada K., Kawamoto A., Matsubayashi K., Nishinag M., Kimura S., and Ozawa T. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10 (1992) 875-878
4. Verdecchia P., Schillaci G., Gatteschi C., Zampi I., Battistelli M., Bartoccini C., and Porcellati C. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 88 (1993) 986-992
5. Verdecchia P., Porcellati C., Schillaci G., Borgioni C., Ciucci A., Battistelli M., Guerrieri M., Gatteschi C., Zampi I., Santucci A., Santucci C., and Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24 (1994) 793-801
6. von Känel R., Jain S., Mills P.J., Nelesen R.A., Adler K.A., Hong S., Perez C.J., and Dimsdale J.E. Relation of nocturnal blood pressure dipping to cellular adhesion, inflammation and hemostasis. J Hypertens 22 (2004) 2087-2093
7. Lee K.W., Blann A.D., and Lip G.Y. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 18 (2005) 104-115
8. Desideri G., and Ferri C. Endothelial activation. Sliding door to atherosclerosis. Curr Pharm Des 11 (2005) 2163-2175
9. Andrè P., Nannizzi-Alaimo L., Prasad A.K., and Phillips D.R. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
10. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
11. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., and Kroczek R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
12. Mach F., Schonbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., and Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94 (1997) 1931-1936
13. Graf D., Muller S., Korthauer U., van Kooten C., Weise C., and Kroczek R.A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25 (1995) 1749-1754
14. Desideri G., and Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 289 (2003) 1781-1782
15. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., Falco A., Cuccurullo F., and Davì G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation 106 (2002) 399-402
16. Aukrust P., Müller F., Ueland T., Berget T., Aaser E., Brunsvig A., Solum N.O., Forfang K., Frøland S.S., and Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation 100 (1999) 614-620
17. Schönbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
18. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., Gibson C.M., Cannon C.P., Braunwald E., and Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
19. Minuz P., Patrignani P., Gaino S., Seta F., Capone M.L., Tacconelli S., Degan M., Faccini G., Fornasiero A., Talamini G., Tommasoli R., Arosio E., Santonastaso C.L., Lechi A., and Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension 43 (2004) 64-70
20. Teran E., Escudero C., and Vivero S. Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide 7 (2002) 217-220
21. Omboni S., Parati G., Palatini P., Vanasia A., Muiesan M.L., Cuspidi C., and Mancia G. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. J Hypertens 16 (1998) 733-738
22. Blake G.J., Ostfeld R.J., Yucel E.K., Varo N., Schonbeck U., Blake M.A., Gerhard M., Ridker P.M., Libby P., and Lee R.T. Should soluble CD40 ligand be measured from serum or plasma samples?. Arterioscler Thromb Vasc Biol 23 (2003) 1129-1130
23. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intima plus media thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
24. Yan J.C., Ma G.S., Wu Z.G., Kong X.T., Zong R.Q., and Zhan L.Z. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 355 (2005) 191-196
25. Patel J.V., Lim H.S., Nadar S., Tayebjee M., Hughes E.A., and Lip G.Y. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 24 (2006) 117-121
26. Sonmez A., Dogru T., Yilmaz M.I., Ocal R., Ozgurtas T., Kilic S., Eyileten T., Tasci I., Erbil K., and Kocar I.H. Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens 27 (2005) 629-634
27. Tsioufis C., Lambrou S., Stefanadis C., Antoniadis D.I., Kallikazaros I.E., Pitsavos C.E., and Tioutouzas P.K. Microalbuminuria is associated with impaired arterial mechanics in essential hypertension. Am J Cardiol 86 (2000) 797-801
28. Blann A.D., Nadar S., and Lip G.Y.H. Pharmacological modulation of platelet function in hypertension. Hypertension 42 (2003) 1-7